AP2015008493A0 - Topical ophthalmological pharmaceutical composition containing regorafenib - Google Patents

Topical ophthalmological pharmaceutical composition containing regorafenib

Info

Publication number
AP2015008493A0
AP2015008493A0 AP2015008493A AP2015008493A AP2015008493A0 AP 2015008493 A0 AP2015008493 A0 AP 2015008493A0 AP 2015008493 A AP2015008493 A AP 2015008493A AP 2015008493 A AP2015008493 A AP 2015008493A AP 2015008493 A0 AP2015008493 A0 AP 2015008493A0
Authority
AP
ARIPO
Prior art keywords
pharmaceutical composition
composition containing
ophthalmological pharmaceutical
topical ophthalmological
containing regorafenib
Prior art date
Application number
AP2015008493A
Other languages
English (en)
Inventor
Bernd Riedl
Annett Richter
Andreas Ohm
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AP2015008493A0 publication Critical patent/AP2015008493A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
AP2015008493A 2012-12-21 2013-12-21 Topical ophthalmological pharmaceutical composition containing regorafenib AP2015008493A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12198892 2012-12-21

Publications (1)

Publication Number Publication Date
AP2015008493A0 true AP2015008493A0 (en) 2015-05-31

Family

ID=47458742

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008493A AP2015008493A0 (en) 2012-12-21 2013-12-21 Topical ophthalmological pharmaceutical composition containing regorafenib

Country Status (27)

Country Link
US (2) US20140179745A1 (fr)
EP (1) EP2934481A1 (fr)
JP (1) JP2016507505A (fr)
KR (1) KR20150100670A (fr)
CN (1) CN104955443A (fr)
AP (1) AP2015008493A0 (fr)
AR (1) AR094104A1 (fr)
AU (1) AU2013364004A1 (fr)
BR (1) BR112015014078A2 (fr)
CA (1) CA2895804A1 (fr)
CL (1) CL2015001701A1 (fr)
CR (1) CR20150327A (fr)
CU (1) CU20150063A7 (fr)
DO (1) DOP2015000155A (fr)
EA (1) EA201500669A1 (fr)
EC (1) ECSP15026386A (fr)
IL (1) IL238791A0 (fr)
MA (1) MA38215A1 (fr)
MX (1) MX2015007488A (fr)
PE (1) PE20151784A1 (fr)
PH (1) PH12015501407A1 (fr)
SG (1) SG11201503838WA (fr)
TN (1) TN2015000280A1 (fr)
TW (1) TW201431568A (fr)
UY (1) UY35183A (fr)
WO (1) WO2014100797A1 (fr)
ZA (1) ZA201505196B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024205A1 (fr) * 2016-05-16 2017-11-23 Delivra Inc. Formulations transdermiques pour l'administration de celecoxib et leur utilisation dans le traitement de maladies et de pathologies sensibles au celcoxib
CN112834485B (zh) * 2021-02-07 2022-03-29 西南交通大学 激光诱导击穿光谱元素定量分析的一种非定标方法
KR102413226B1 (ko) 2021-08-26 2022-06-23 충북대학교 산학협력단 레고라페닙을 유효성분으로 포함하는 항노화 조성물
KR102813302B1 (ko) 2022-05-30 2025-05-28 (주)레비레스코 감태 추출물, 귤피 추출물, 및 녹차 추출물을 유효성분으로 포함하는 자외선에 대한 세포 보호용 또는 mmp-1 발현 억제용 조성물
CA3264785A1 (fr) 2022-08-12 2024-02-15 Jazz Pharmaceuticals Research Uk Limited Formes posologiques solides orales comprenant des cannabinoïdes
CN118141743A (zh) * 2024-02-07 2024-06-07 中山大学 一种眼部注射制剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
SI1885336T1 (sl) 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
WO2006133411A1 (fr) 2005-06-08 2006-12-14 Targegen, Inc. Methodes et preparations pour le traitement de troubles oculaires
EP1968594B1 (fr) 2005-11-29 2010-09-29 GlaxoSmithKline LLC Traitement de troubles neovasculaires oculaires comme par example dègèneresence maculaire, uveite et oedème maculaire
EP1962828A1 (fr) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryle-uree pour le traitement de maladies inflammatoires de la peau, l'oeil et/ou l'oreille
WO2007076358A1 (fr) 2005-12-23 2007-07-05 Alcon, Inc. Preparation pharmaceutique pour l'administration, dans l'oeil, de composes inhibiteurs des récepteurs tyrosine kinases (rtki)
WO2008027341A2 (fr) 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2012525415A (ja) 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
JP2012533562A (ja) 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
EA201400064A1 (ru) * 2011-06-28 2014-05-30 Байер Хелфкеэ Ллк Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб

Also Published As

Publication number Publication date
WO2014100797A1 (fr) 2014-06-26
US20140179745A1 (en) 2014-06-26
AU2013364004A1 (en) 2015-06-04
MX2015007488A (es) 2015-09-04
AR094104A1 (es) 2015-07-08
KR20150100670A (ko) 2015-09-02
CN104955443A (zh) 2015-09-30
CU20150063A7 (es) 2015-11-27
PH12015501407A1 (en) 2015-09-07
IL238791A0 (en) 2015-06-30
MA38215A1 (fr) 2017-01-31
JP2016507505A (ja) 2016-03-10
DOP2015000155A (es) 2015-08-31
EP2934481A1 (fr) 2015-10-28
BR112015014078A2 (pt) 2018-05-15
CR20150327A (es) 2015-09-14
EA201500669A1 (ru) 2015-12-30
ECSP15026386A (es) 2016-01-29
TW201431568A (zh) 2014-08-16
US20150328145A1 (en) 2015-11-19
ZA201505196B (en) 2017-11-29
SG11201503838WA (en) 2015-07-30
TN2015000280A1 (en) 2016-10-03
CA2895804A1 (fr) 2014-06-26
UY35183A (es) 2014-07-31
CL2015001701A1 (es) 2015-10-16
PE20151784A1 (es) 2015-11-25

Similar Documents

Publication Publication Date Title
ZA201406233B (en) Pharmaceutical composition and administration thereof
ZA201501394B (en) Coated pharmaceutical composition containing regorafenib
PL3181122T3 (pl) Kompozycja farmaceutyczna dazatynibu
IL234831A0 (en) Medical preparations for combined treatment
ZA201501930B (en) Pharmaceutical composition
EP2832730A4 (fr) Composition pharmaceutique contenant du mirabegron
ZA201400646B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
IL266415A (en) Innovative pharmaceutical composition
SG11201403875VA (en) Oral pharmaceutical composition
ZA201505196B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
IL237146A0 (en) Pharmaceutical compound containing Rabamipide
ZA201502987B (en) Pharmaceutical composition
EP2851074A4 (fr) Composition pharmaceutique analgésique
LT2638894T (lt) Farmacinė kompozicija, turinti fosfolipido
EP2930175A4 (fr) Nouveau dérivé d'octahydropyridoquinazoline, composition pharmaceutique le contenant, et utilisations pour ledit dérivé et ladite composition
ZA201400751B (en) Pharmaceutical composition
GB201204597D0 (en) Topical pharmaceutical formulation
GB201221130D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
AU2012904295A0 (en) Pharmaceutical composition
HUE043019T2 (hu) Gyógyszerészeti készítmények kombinációs terápia céljára